Light Horse Therapeutics Secures $62M in Series A Funding for Cutting-Edge Drug Discovery Technology

Light Horse Therapeutics, an innovative small molecule drug discovery firm based in San Diego, has recently secured $62 million in funding to accelerate its pioneering research in oncology therapeutics. Founded by a trio of esteemed academics—Brian Liau from Harvard, Ben Cravatt from Scripps, and Nathanael Gray from Stanford—the company leverages advanced tools from chemical and computational biology, as well as precision genome editing techniques. This strategic funding round, which includes contributions from existing backers including Versant Ventures and Mubadala Capital, aims to enhance the company’s capabilities in identifying functional and ligandable sites on high-value oncology protein targets for therapeutic intervention. With this capital infusion, Light Horse Therapeutics is set to advance its R&D efforts and expand its portfolio of drug candidates aimed at treating some of the most challenging cancers. The funding will not only bolster internal resources but also facilitate collaborations that could bring new, targeted therapies to market much faster. As Light Horse Therapeutics continues to push the boundaries of science and technology, their mission remains clear: to revolutionize cancer treatment and make a significant impact on patient outcomes. This latest financial milestone underscores the confidence investors have in the company's vision and its potential to transform the landscape of oncology therapeutics.